Back to Search
Start Over
Lixisenatide reduces glycaemic variability in insulin-treated patients with type 2 diabetes.
- Source :
-
Diabetes, obesity & metabolism [Diabetes Obes Metab] 2017 Sep; Vol. 19 (9), pp. 1317-1321. Date of Electronic Publication: 2017 May 05. - Publication Year :
- 2017
-
Abstract
- Chronic hyperglycaemia and glucose variability are associated with the development of chronic diabetes-related complications. We conducted a pooled analysis of patient-level data from three 24-week, randomized, phase III clinical trials to evaluate the impact of lixisenatide (LIXI) on glycaemic variability (GV) vs placebo as add-on to basal insulin. The main outcome GV measures were standard deviation (s.d.), mean amplitude of glycaemic excursions (MAGE), mean absolute glucose (MAG) level, area under the curve for fasting glucose (AUC-F), and high (HBGI) and low blood glucose index (LBGI). The change in GV metrics over 24 weeks and relationships among baseline GV, patient characteristics and outcomes were assessed. Data were pooled from 1198 patients (665 LIXI, 533 placebo). Values for s.d., MAG level, MAGE, HBGI, and AUC-F significantly decreased with LIXI vs placebo, while LBGI values were unchanged. Higher baseline GV measures correlated with older age, longer type 2 diabetes duration, lower body mass index, higher baseline glycated/haemogobin, greater reduction in postprandial glucose (PPG) level, and higher rates of symptomatic hypoglycaemia. These data show that LIXI added to basal insulin significantly reduced GV and PPG excursions vs placebo, without increasing the risk of hypoglycaemia (LBGI).<br /> (© 2017 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.)
- Subjects :
- Blood Glucose analysis
Blood Glucose Self-Monitoring
Cohort Studies
Diabetes Mellitus, Type 2 blood
Double-Blind Method
Drug Resistance
Drug Therapy, Combination adverse effects
Follow-Up Studies
Glucagon-Like Peptide-1 Receptor metabolism
Glycated Hemoglobin analysis
Humans
Hyperglycemia physiopathology
Hypoglycemia chemically induced
Hypoglycemia physiopathology
Hypoglycemic Agents adverse effects
Insulin adverse effects
Intention to Treat Analysis
Middle Aged
Peptides adverse effects
Reproducibility of Results
Severity of Illness Index
Diabetes Mellitus, Type 2 drug therapy
Glucagon-Like Peptide-1 Receptor agonists
Hyperglycemia prevention & control
Hypoglycemia prevention & control
Hypoglycemic Agents therapeutic use
Insulin therapeutic use
Peptides therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1463-1326
- Volume :
- 19
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- Diabetes, obesity & metabolism
- Publication Type :
- Academic Journal
- Accession number :
- 28256054
- Full Text :
- https://doi.org/10.1111/dom.12930